Research affiliations

Research groups

Research summary

My program of research focuses on the regulation of mitochondrial function and metabolism during cardiac and skeletal muscle differentiation and remodeling, including disease related conditions such as hypoxia/ischemia, diabetic cardiomyopathy, and insulin resistance; as well as physiological stimuli such as exercise and contractile activity. My laboratory utilizes cellular, molecular, and multi-omics approaches to understand mitochondrial function, dynamics, and turn-over including the regulation of mitophagy and mitochondrial permeability transition. Specifically, my laboratory studies the transcriptional regulation and post-translational modification of the Bcl-2 family members Nix and Bnip3 utilizing both primary and immortalized cells, differentiated human induced pluripotent stem cells, and conditional knockout mice.


Over the course of my training, I have studied in 3 high-profile Canada research laboratories, each with a track-record for excellence. I began my graduate training with Dr. David Hood in the School of Kinesiology and Health Science at York University. During my MSc training with Dr. Hood, I studied how skeletal muscle mitochondria physiologically adapt to chronic contractile activity, with a specific interest in the mitochondrial protein import pathway and the molecular regulation of the mitochondrial transcription factor A (Tfam). During my PhD training, I studied with Dr. John McDermott in the Department of Biology at York University. Here, I examined the importance of the myocyte enhancer factor 2 (MEF2) family of transcription factors in muscle differentiation. My dissertation was directed toward understanding how protein kinase A (PKA) negatively regulates MEF2 activity and muscle gene transcription. In addition, we identified a novel MEF2 interacting partner, the protein phosphatase 1α, and determined how this mechanism regulates myocardin expression in vascular smooth muscle cells through CPI-17. Finally, I trained as a postdoctoral fellow with Dr. Lorrie Kirshenbaum at the St. Boniface Research Centre, where I studied the molecular regulation of hypoxia-induced programmed cell death in cardiac myocytes. Here, I was involved in the discovery and biological characterization of a novel hypoxia-inducible splice variant of the death-gene Bnip3. We discovered that this splice variant acts as an endogenous inhibitor, serving to promote cardiac myocyte survival.

As an independent scientist, I am pursuing my own experimental interests, such as muscle lipotoxicity and diabetes-associated complications of the cardiovascular system. Although my program is based on the expertise I acquired during my training, all current projects in my laboratory are based on novel observations since I became independent. Current projects in my laboratory involve: 1) the regulation of Nix by Myocardin during cardiac development and disease; 2) the evaluation of Nix-induced mitophagy and the role in muscle and heart insulin resistance; 3) determining how Bnip3 regulates neonatal cardiomyocyte cell death and proliferation during hypoxic injury; and 4) evaluating the role of Nix and Bnip3 in rhabdomyosarcoma.



  • CIHR-MHRC Post-doctoral fellowship (2011–2012)
  • CIHR IMPACT Strategic Training Program Post-doctoral fellowship (2011-2012)
  • Arnold Naimark Young Investigator Award (2011)

ORCID profile

Visit Joseph Gordon's ORCID profile for a complete listing.

Joseph Gordon's profile

Google Scholar

Visit Joseph Gordon's Google Scholar page.

Joseph Gordon's page


Visit Joseph Gordon's ResearchGate profile.

Joseph Gordon's profile